Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISTH0036 for diabetic macular edema and neovascular age-related macular degeneration
2021-001213-36Phase 2Completed
- Sponsor
- Isarna Therapeutics
- Start
- Mar 2021
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tgf-β2 antisense oligonucleotide in diabetic macular edema (DME) and exudative macular degeneration (3 arms), sponsored by Isarna Therapeutics. Started Mar 2021; status: completed.
02
Drugs
tgf-β2 antisense oligonucleotide
03
Conditions
diabetic macular edema (DME)exudative macular degeneration
Beyond the preview
Go deeper on 2021-001213-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001213-36.